{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:26:30Z","timestamp":1744259190372,"version":"3.40.4"},"reference-count":87,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2012,9,30]]},"DOI":"10.2217\/fon.12.112","type":"journal-article","created":{"date-parts":[[2012,10,3]],"date-time":"2012-10-03T10:25:44Z","timestamp":1349259944000},"page":"1135-1147","source":"Crossref","is-referenced-by-count":18,"title":["The Changing Landscape of Therapeutic Strategies for Recurrent Ovarian Cancer"],"prefix":"10.1080","volume":"8","author":[{"given":"Klaus H","family":"Baumann","sequence":"first","affiliation":[{"name":"University Hospital of Giessen & Marburg, Marburg Site, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Wagner","sequence":"additional","affiliation":[{"name":"University Hospital of Giessen & Marburg, Marburg Site, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"du Bois","sequence":"additional","affiliation":[{"name":"Department of Gynaecology & Gynaecological Oncology, Kliniken Essen Mitte, Essen, Germany"},{"name":"University Hospital of Giessen & Marburg, Marburg Site, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2012,10,3]]},"reference":[{"key":"e_1_3_2_3_1_1","first-page":"144","article-title":"Long-term follow-up confirms a survival advantage of the paclitaxel\u2013cisplatin regimen over the cyclophosphamide\u2013cisplatin combination in advanced ovarian cancer.","volume":"13","author":"Piccart MJ","year":"2003","unstructured":"Piccart MJ , BertelsenK, StuartGet al. Long-term follow-up confirms a survival advantage of the paclitaxel\u2013cisplatin regimen over the cyclophosphamide\u2013cisplatin combination in advanced ovarian cancer. Int. J. Gynecol. Cancer 13, 144\u2013148 (2003).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr421"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.5-1-26"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31821bb8aa"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20694"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2004.01.024"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030550"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-94"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2011.0010"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2011.0009"},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg036"},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390"},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103799"},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61268-8"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.10.060"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.08.027"},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2005.00430.x"},{"issue":"10","key":"e_1_3_2_3_18_1","first-page":"x235","article-title":"The role of surgery in advanced and recurrent ovarian cancer.","volume":"17","author":"du Bois A","year":"2006","unstructured":"du Bois A , HarterP. The role of surgery in advanced and recurrent ovarian cancer.Ann. Oncol.17(Suppl. 10), x235\u2013x240 (2006).","journal-title":"Ann. Oncol."},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31820aaafd"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-009-0357-0"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.2217\/WHE.11.52"},{"key":"e_1_3_2_3_22_1","first-page":"CD007822","article-title":"Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer.","volume":"16","author":"Galaal K","year":"2010","unstructured":"Galaal K , NaikR, BristowREet al. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst. Rev. 16, CD007822 (2010).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13718-X"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.0913"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.7519"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.08.011"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.0505"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds003"},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e32834a62b4"},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq357"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.05.033"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/IGC.0b013e3181e273a8"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1381"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.3178"},{"key":"e_1_3_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq352"},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq353"},{"key":"e_1_3_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr321"},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e318217b30b"},{"key":"e_1_3_2_3_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr441"},{"key":"e_1_3_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.2165\/11591720-000000000-00000"},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.8911"},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr149"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2006.00728.x"},{"key":"e_1_3_2_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.03.036"},{"key":"e_1_3_2_3_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq780"},{"key":"e_1_3_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.02.019"},{"key":"e_1_3_2_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70244-3"},{"key":"e_1_3_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.08.033"},{"key":"e_1_3_2_3_49_1","doi-asserted-by":"publisher","DOI":"10.1159\/000320602"},{"key":"e_1_3_2_3_50_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.5045","article-title":"PRECEDENT: a randomized Phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.","volume":"29","author":"Naumann RW","year":"2011","unstructured":"Naumann RW , ColemanRL, BurgerRAet al. PRECEDENT: a randomized Phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. J. Clin. Oncol. 29(Suppl.), Abstract 5045 (2011).","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"e_1_3_2_3_51_1","article-title":"Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer.","volume":"28","author":"Emons G","year":"2010","unstructured":"Emons G , TomovS, HarterPet al. Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer. J. Clin. Oncol. 28(15 Suppl.), Abstract 5035 (2010).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.9215"},{"issue":"15","key":"e_1_3_2_3_53_1","article-title":"AURELIA: a randomized Phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).","volume":"30","author":"Pujade-Lauraine E","year":"2012","unstructured":"Pujade-Lauraine E , HilpertF, WeberBet al. AURELIA: a randomized Phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J. Clin. Oncol. 30(15 Suppl.), Abstract LBA5002 (2012).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_54_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.18_suppl.lba5000","article-title":"Randomized Phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a GCIG and EORTC\u2013GCG study.","volume":"30","author":"Vergote I","year":"2012","unstructured":"Vergote I , JolyF, KatsarosDet al. Randomized Phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a GCIG and EORTC\u2013GCG study. J. Clin. Oncol. 30(Suppl.), Abstract LBA5000 (2012).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.104"},{"key":"e_1_3_2_3_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.05.005"},{"key":"e_1_3_2_3_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.10.053"},{"key":"e_1_3_2_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.12.003"},{"key":"e_1_3_2_3_59_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2308"},{"key":"e_1_3_2_3_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.3354"},{"key":"e_1_3_2_3_61_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834011417039"},{"key":"e_1_3_2_3_62_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030042"},{"key":"e_1_3_2_3_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105535"},{"key":"e_1_3_2_3_64_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.5004","article-title":"A Phase II trial of iniparib (BSI-201) in combination with gemcitabine\/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer.","volume":"29","author":"Penson RT","year":"2011","unstructured":"Penson RT , WhalenC, LasondeBet al. A Phase II trial of iniparib (BSI-201) in combination with gemcitabine\/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. J. Clin. Oncol. 29(Suppl.), Abstract 5004 (2011).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602752"},{"key":"e_1_3_2_3_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2006.00749.x"},{"key":"e_1_3_2_3_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-011-0835-2"},{"key":"e_1_3_2_3_68_1","first-page":"74","article-title":"The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study.","volume":"16","author":"Spiliotis J","year":"2011","unstructured":"Spiliotis J , VaxevanidouA, SergouniotisFet al. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study. J. BUON 16, 74\u201379 (2011).","journal-title":"J. BUON"},{"key":"e_1_3_2_3_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21682"},{"key":"e_1_3_2_3_70_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-009-0878-6"},{"key":"e_1_3_2_3_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-009-0667-4"},{"key":"e_1_3_2_3_72_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0275"},{"key":"e_1_3_2_3_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.6.1562"},{"key":"e_1_3_2_3_74_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2762"},{"key":"e_1_3_2_3_75_1","first-page":"249","article-title":"Drug evaluation: Reolysin \u2013 wild-type reovirus as a cancer therapeutic.","volume":"8","author":"Stoeckel J","year":"2006","unstructured":"Stoeckel J , HayJG. Drug evaluation: Reolysin \u2013 wild-type reovirus as a cancer therapeutic.Curr. Opin Mol. Ther.8, 249\u2013260 (2006).","journal-title":"Curr. Opin Mol. Ther."},{"issue":"5","key":"e_1_3_2_3_76_1","first-page":"e670","article-title":"Potentiation of a p53\u2013SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm Phase II study.","volume":"131","author":"Vermeij R","year":"2011","unstructured":"Vermeij R , LeffersN, HoogeboomBNet al. Potentiation of a p53\u2013SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm Phase II study. Int. J. Cancer 131(5), e670\u2013e680 (2011).","journal-title":"Int. J. Cancer"},{"key":"e_1_3_2_3_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1100-9"},{"key":"e_1_3_2_3_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.08.007"},{"key":"e_1_3_2_3_79_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-439"},{"key":"e_1_3_2_3_80_1","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1097\/IGC.0b013e31822c750d","article-title":"Intraoperative electron beam radiotherapy (IOERT) in the management of recurrent ovarian malignancies.","volume":"21","author":"Barney BM","year":"2011","unstructured":"Barney BM , PetersenIA, DowdySCet al. Intraoperative electron beam radiotherapy (IOERT) in the management of recurrent ovarian malignancies. Int. J. Gynecol. Cancer 21, 1225\u20131231 (2011).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"e_1_3_2_3_81_1","doi-asserted-by":"publisher","DOI":"10.1177\/030089161109700509"},{"key":"e_1_3_2_3_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.10.018"},{"key":"e_1_3_2_3_83_1","article-title":"Olaparib plus paclitaxel plus carboplatin (P\/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label Phase II study.","volume":"30","author":"Oza A","year":"2012","unstructured":"Oza A , CibulaD, OakninAet al. Olaparib plus paclitaxel plus carboplatin (P\/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label Phase II study. J. Clin. Oncol. 30(Suppl.), Abstract 5001 (2012).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.04.001"},{"key":"e_1_3_2_4_2_1","unstructured":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie Studiengruppe (AGO Study Group Germany). www.ago-ovar.de"},{"key":"e_1_3_2_4_3_1","unstructured":"U.S. National Institutes of Health Clinical Trial Registry. www.clinicaltrials.gov"},{"key":"e_1_3_2_4_4_1","unstructured":"Mulitcenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies Mito-Group. www.mito-group.it"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.12.112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T22:26:05Z","timestamp":1744237565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.12.112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,30]]},"references-count":87,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9,30]]}},"alternative-id":["10.2217\/fon.12.112"],"URL":"https:\/\/doi.org\/10.2217\/fon.12.112","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"type":"print","value":"1479-6694"},{"type":"electronic","value":"1744-8301"}],"subject":[],"published":{"date-parts":[[2012,9,30]]}}}